[1]邹洪强,田洪芹,张艳平,等.阿柏西普治疗眼底血管性疾病的临床研究新进展[J].眼科新进展,2017,37(9):894-897.[doi:10.13389/j.cnki.rao.2017.0227]
　ZOU Hong-Qiang,TIAN Hong-Qin,ZHANG Yan-Ping,et al.Recent advances in clinical research on aflibercept treating fundus vascular diseases[J].Recent Advances in Ophthalmology,2017,37(9):894-897.[doi:10.13389/j.cnki.rao.2017.0227]
点击复制

阿柏西普治疗眼底血管性疾病的临床研究新进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年9期
页码:
894-897
栏目:
文献综述
出版日期:
2017-09-05

文章信息/Info

Title:
Recent advances in clinical research on aflibercept treating fundus vascular diseases
作者:
邹洪强; 田洪芹; 张艳平; 李荣欣
261031　山东省潍坊市，潍坊医学院附属医院药学部（邹洪强，李荣欣）；261041　山东省潍坊市，潍坊市肿瘤医院药剂科（邹洪强，张艳平）；261045　山东省潍坊市，阳光融合医院儿科（田洪芹）
Author(s):
ZOU Hong-Qiang; TIAN Hong-Qin; ZHANG Yan-Ping; LI Rong-Xin
Department of Pharmacy，Affiliated Hospital of Weifang Medical College（ZOU Hong-Qiang，LI Rong-Xin），Weifang 261031，Shandong Province，China；Department of Pharmacy，Weifang Cancer Hospital（ZOU Hong-Qiang，ZHANG Yan-Ping），Weifang 261041，Shandong Province，China；Department of Pediatrics，Sunshine Union Hospital（TIAN Hong-Qin），Weifang 261045，Shandong Province，China
关键词:
阿柏西普; 血管内皮生长因子; 黄斑变性; 黄斑水肿
Keywords:
aflibercept; vascular endothelial growth factor; macular degeneration; macular edema
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2017.0227
文献标志码:
A
摘要:
阿柏西普是人血管内皮生长因子（vascular endothelial growth factor，VEGF）受体1和受体2胞外区结合域与人免疫球蛋白Fc段重组形成的融合蛋白，是一种新的抗VEGF药物，通过与VEGF紧密结合，降低血管通透性，进一步抑制新生血管的生成。多项大型Ⅲ期临床试验已验证了阿柏西普治疗湿性老年性黄斑变性、静脉阻塞黄斑水肿、糖尿病黄斑水肿和其他血管性眼底病的疗效，结果显示玻璃体内注射阿柏西普能够提高患者视力并且减轻眼底病变程度，为眼科医师提供了一种新的药物选择。本综述就阿柏西普的药理学特点以及它在眼底血管性疾病中的应用、疗效和安全性等方面进行论述。
Abstract:
Aflibercept is a soluble fusion protein which combines ligand-binding elements taken from the extracellular components of vascular endothelial growth factor （VEGF） receptor-1 and receptor-2 fused to the Fc portion of IgG，and it is a novel anti-VEGF drug，which can reduce vascular permeability and inhibit neoangiogenesis by binding VEGF tightly.A large number of phase Ⅲ clinical trials have demonstrated the satisfactory outcomes of aflibercept in the management of neovascular age-related macular degeneration，macular edema secondary to retinal vein occlusion or macular edema and other retinal vascular diseases.Moreover，intravitreal injection of aflibercept can improve the visual acuity and attenuate the fundus lesion，which provides a new drug option for physicians.The review will summarize the chemical properties of aflibercept and its application，safety and efficacy of aflibercept for the treatment of retinal vascular diseases.

参考文献/References:

［1］　SARWAR S，BAKBAK B，SADIQ MA，SEPAH YJ，SHAH SM，IBRAHIM M，et al.Fusion proteins：aflibercept（VEGF Trap-Eye）［J］.Dev Ophthalmol，2016，55：282-294.
［2］　HOLASH J，DAVIS S，PAPADOPOULOS N，CROLL SD，HO L，RUSSELL M，et al.VEGF-Trap：a VEGF blocker with potent antitumor effects［J］.Proc Natl Acad Sci USA，2002，99（17）：11393-11398.
［3］　DE OLIVEIRA DIAS JR，DE ANDRADE GC，NOVAIS EA，FARAH ME，RODRIGUES EB.Fusion proteins for treatment of retinal diseases：aflibercept，ziv-aflibercept，and conbercept［J］.Int J Retina Vitreous，2016，2（1）：3.
［4］　OLSSON AK，DIMBERG A，KREUGER J，CLAESSON-WELSH L.VEGF receptor signalling-in control of vascular function［J］.Nat Rev Mol Cell Biol，2006，7（5）：359-371.
［5］　RUDGE JS，THURSTON G，DAVIS S，PAPADOPOULOS N，GALE N，WIEGAND SJ，et al.VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases，and VelociGene-based discovery of the next generation of angiogenesis targets［J］.Cold Spring Harb Symp Quant Biol，2005，70：411-418.
［6］　CURSIEFEN C，CHEN L，BORGES LP，JACKSON D，CAO J，RADZIEJEWSKI C，et al.VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment［J］.J Clin Invest，2004，113（7）：1040-1050.
［7］　LOWE J，ARAUJO J，YANG J，REICH M，OLDENDORP A，SHIU V，et al.Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo［J］.Exp Eye Res，2007，85（4）：425-430.
［8］　BAKRI SJ，SNYDER MR，REID JM，PULIDO JS，EZZAT MK，SINGH RJ.Pharmacokinetics of intravitreal ranibizumab（Lucentis）［J］.Ophthalmology，2007，114（12）：2179-2182.
［9］　BAKRI SJ，SNYDER MR，REID JM，PULIDO JS，SINGH RJ.Pharmacokinetics of intravitreal bevacizumab（Avastin）［J］.Ophthalmology，2007，114（5）：855-859.
［10］　STEWART MW，ROSENFELD PJ.Predicted biological activity of intravitreal VEGF Trap［J］.Br J Ophthalmol，2008，92（5）：667-668.
［11］　JULIEN S，BIESEMEIER A，TAUBITZ T，SCHRAERMEYER U.Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes［J］.Br J Ophthalmol，2014，98（6）：813-825.
［12］　NGUYEN QD，SHAH SM，BROWNING DJ，HUDSON H，SONKIN P，HARIPRASAD SM，et al.A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration［J］.Ophthalmology，2009，116（11）：2141-2148.
［13］　BROWN DM，HEIER JS，CIULLA T，BENZ M，ABRAHAM P，YANCOPOULOS G，et al.Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration［J］.Ophthalmology，2011，118（6）：1089-1097.
［14］　HEIER JS，BROWN DM，CHONG V，KOROBELNIK JF，KAISER PK，NGUYEN QD，et al.Intravitreal aflibercept（VEGF trap-eye） in wet age-related macular degeneration［J］.Ophthalmology，2012，119（12）：2537-2548.
［15］　NGUYEN QD，CAMPOCHIARO PA，SHAH SM，BROWNING DJ，HUDSON HL，SONKIN PL，et al.Evaluation of very high-and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration［J］.J Ocul Pharmacol Ther，2012，28（6）：581-588.
［16］　HEIER JS，BOYER D，NGUYEN QD，MARCUS D，ROTH DB，YANCOPOULOS G，et al.The 1-year results of CLEAR-IT 2，a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing［J］.Ophthalmology，2011，118（6）：1098-1106.
［17］　DO DV，SCHMIDT-ERFURTH U，GONZALEZ VH，GORDON CM，TOLENTINO M，BERLINER AJ，et al.The DA VINCI Study：phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema［J］.Ophthalmology，2011，118（9）：1819-1826.
［18］　DO DV，NGUYEN QD，BOYER D，SCHMIDT-ERFURTH U，BROWN DM，VITTI R，et al.One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema［J］.Ophthalmology，2012，119（8）：1658-1665.
［19］　KOROBELNIK JF，DO DV，SCHMIDT-ERFURTH U，BOYER DS，HOLZ FG，HEIER JS，et al.Intravitreal aflibercept for diabetic macular edema［J］.Ophthalmology，2014，121（11）：2247-2254.
［20］　CAMPOCHIARO PA，CLARK WL，BOYER DS，HEIER JS，BROWN DM，VITTI R，et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion：the 24-week results of the VIBRANT study［J］.Ophthalmology，2015，122（3）：538-544.
［21］　WELLS JA，GLASSMAN AR，AYALA AR，JAMPOL LM，BRESSLER NM，BRESSLER SB，et al.Aflibercept，bevacizumab，or ranibizumab for diabetic macular edema：two-year results from a comparative effectiveness randomized clinical trial［J］.Ophthalmology，2016，123（6）：1351-1359.
［22］　HEIER JS，CLARK WL，BOYER DS，BROWN DM，VITTI R，BERLINER AJ，et al.Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion：two-year results from the COPERNICUS study［J］.Ophthalmology，2014，121（7）：1414-1420.
［23］　OGURA Y，ROIDER J，KOROBELNIK JF，HOLZ FG，SIMADER C，SCHMIDT-ERFURTH U，et al.Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion：18-month results of the phase 3 GALILEO study［J］.Am J Ophthalmol，2014，158（5）：1032-1038.
［24］　BOYER D，HEIER J，BROWN DM，CLARK WL，VITTI R，BERLINER AJ，et al.Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion：six-month results of the phase 3 COPERNICUS study［J］.Ophthalmology，2012，119（5）：1024-1032.
［25］　CLARK WL，BOYER DS，HEIER JS，BROWN DM，HALLER JA，VITTI R，et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion：52-week results of the VIBRANT Study［J］.Ophthalmology，2016，123（2）：330-336.
［26］　IKUNO Y，OHNO-MATSUI K，WONG TY，KOROBELNIK JF，VITTI R，LI T，et al.Intravitreal aflibercept injection in patients with myopic choroidal neovascularization：The MYRROR Study［J］.Ophthalmology，2015，122（6）：1220-1227.
［27］　PITCHER JD，WITKIN AJ，DECROOS FC，HO AC.A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy：the CONTAIN study［J］.Br J Ophthalmol，2015，99（6）：848-852.
［28］　KOWALCZUK L，MATET A，DIRANI A，DARUICH A，AMBRESIN A，MANTEL I，et al.Efficacy of intravitreal aflibercept in macular telangiectasia type 1 is linked to the ocular angiogenic profile［J］.Retina，2016，36（1）：28-36.
［29］　SUKGEN EA，SOKER G，KOCLUK Y，GULEK B.Effect of intravitreal aflibercept on central retinal arterial blood flow in type 1 retinopathy of prematurity［J］.Eur J Ophthalmol，2017，101（6）：231-240.
［30］　SCHATZ P，SKARIN A，LAVAQUE AJ，LIMA LH，AREVALO JF.Preservation of macular structure and function after intravitreal aflibercept for choroidal neovascularization associated with serpiginous choroiditis［J］.Acta Ophthalmol，2016，94（8）：839-841.
［31］　BRAIMAH IZ，STEWART M，VIDEKAR C，DEDHIA CJ，CHHABLANI J.Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration［J］.Br J Ophthalmol，2017，101（6）：130-195.
［32］　TOUSSAINT BW，KITCHENS JW，MARCUS DM，MILLER DM，KINGDON ML，HOLCOMB D，et al.Intravitreal aflibercept injection for choroidal neovascularization due to presumed ocular histoplasmosis syndrome：The HANDLE Study［J］.Retina，2017，37（8）：1617-1619.

相似文献/References:

[1]程文武 江萍 席祖莲 张汉武 訾世莉 聂军 董彩虹.蛹虫草提取物抑制大鼠角膜新生血管的实验研究[J].眼科新进展,2012,32(5):000.
[2]于静 张明昌.苦参碱对大鼠角膜新生血管的抑制作用[J].眼科新进展,2012,32(6):000.
[3]吴正正 严京 接传红 高健生 陈皆春 宋剑涛.密蒙花方对缺氧状态下脐静脉血管内皮细胞 VEGF-VEGFR 信号转导通路的影响[J].眼科新进展,2012,32(7):000.
[4]庞霞 曲蕴慧 马跃伟 张效房 董敬民 高冬玲.去整合素金属蛋白酶9和血管内皮生长因子蛋白在眼部恶性黑色素瘤中的表达[J].眼科新进展,2012,32(7):000.
[5]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[6]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[7]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.
[8]曾莉 常以力 邵毅.血管内皮生长因子反义寡脱氧核苷酸联合血管生成素-1对糖尿病视网膜病变大鼠视网膜血管渗漏及新生血管生成的影响[J].眼科新进展,2012,32(10):000.
[9]兰兰 惠延年 曾光伟.血管生成素-1对糖尿病大鼠视网膜微血管病变、基质金属蛋白酶和血管内皮生长因子的抑制作用[J].眼科新进展,2012,32(10):000.
[10]谢明捷 吕红彬 何跃 赵春会.炎症因子与糖尿病视网膜病变相关性研究进展[J].眼科新进展,2012,32(10):000.
[11]卢谦益.阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效[J].眼科新进展,2019,39(4):340.[doi:10.13389/j.cnki.rao.2019.0076]
　LU Qian-Yi.Intravitreal aflibercept injection for the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(9):340.[doi:10.13389/j.cnki.rao.2019.0076]
[12]张国明,田娅.阿柏西普在眼科疾病治疗中的应用[J].眼科新进展,2020,40(1):001.[doi:10.13389/j.cnki.rao.2020.0001]
　ZHANG Guoming,TIAN Ya.Advances in application of Aflibercept for treatment of ocular diseases[J].Recent Advances in Ophthalmology,2020,40(9):001.[doi:10.13389/j.cnki.rao.2020.0001]

更新日期/Last Update: 2017-10-12